Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant in Obese Type 2 Diabetic Patients (SOLO)
NCT00478972Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Apr 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Rimonabant with Placebo (2 arms). Primary endpoints: Absolute change from baseline in HbA1C at 36 weeks and Relative change from baseline in body weight at 36 weeks. Started Apr 2007; status: terminated.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT00478972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478972.